Literature DB >> 1632618

Weak base model of amphetamine action.

D Sulzer1, E Pothos, H M Sung, N T Maidment, B G Hoebel, S Rayport.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1632618     DOI： 10.1111/j.1749-6632.1992.tb26020.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  20 in total

1.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

Review 2.  Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.

Authors:  S R Jones; R R Gainetdinov; R M Wightman; M G Caron
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

3.  GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Kiran B Siripurapu; David B Horton; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2016-12-13       Impact factor: 4.432

4.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

5.  In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Authors:  Rajesh Narendran; Brian J Lopresti; Diana Martinez; Neale Scott Mason; Michael Himes; Maureen A May; Dennis C Daley; Julie C Price; Chester A Mathis; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2011-10-31       Impact factor: 18.112

6.  The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity.

Authors:  Timothy S Jarvela; Hoa A Lam; Michael Helwig; Nikolai Lorenzen; Daniel E Otzen; Pamela J McLean; Nigel T Maidment; Iris Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

7.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

8.  Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.

Authors:  Francesca Binda; Concetta Dipace; Erica Bowton; Sabrina D Robertson; Brandon J Lute; Jacob U Fog; Minjia Zhang; Namita Sen; Roger J Colbran; Margaret E Gnegy; Ulrik Gether; Jonathan A Javitch; Kevin Erreger; Aurelio Galli
Journal:  Mol Pharmacol       Date:  2008-07-10       Impact factor: 4.436

9.  Action potentials and amphetamine release antipsychotic drug from dopamine neuron synaptic VMAT vesicles.

Authors:  Kristal R Tucker; Ethan R Block; Edwin S Levitan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

10.  Amphetamine mechanisms and actions at the dopamine terminal revisited.

Authors:  Erin S Calipari; Mark J Ferris
Journal:  J Neurosci       Date:  2013-05-22       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.